U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06888622) titled 'BLAZE-Limiting Approach in NMOSD' on March 14.
Brief Summary: This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651). Between October 2023 (when eculizumab was approved for NMOSD in China) and February 2025, 26 consecutive patients with AQP4-IgG-positive NMOSD received eculizumab, and 9 of them were included in this study.
Study Start Date: Oct. 01, 2023
Study Type: OBSERVATIONAL
Condition:
Neuromyelitis Optica Spectrum Disorders (NMOSD)
Intervention:
DRUG: Eculizumab administration
Eculizumab was administered...